TmPSMA-02 CAR T Cells for Metastatic Castrate-Resistant Prostate Cancer
This study is testing a new type of cell therapy called TmPSMA-02 CAR T cells for men with metastatic castrate-resistant prostate cancer (mCRPC). These are your own immune cells (T cells) that have been specially modified to target prostate cancer. The main goals are to see how safe TmPSMA-02 CAR T cells are, find the highest safe dose, and check if they can be successfully made for each patient. Researchers will also look for early signs of how well the treatment works. You may be eligible if you are an adult man with mCRPC who has received at least one prior standard treatment. The study is currently recruiting up to 30 participants.
- Study design
- This is a Phase I, open-label study, meaning both you and the study team will know which treatment you receive. It will involve up to 30 participants to find the right dose.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your health will be monitored for adverse events for up to 15 years after the treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
TmPSMA-02 in mCRPC
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Number of subjects with dose limiting toxicities (DLTs)28 days after TmPSMA-02 CAR T cell infusion
- Determination of maximum tolerated dose (MTD)28 days after TmPSMA-02 CAR T cell infusion
- Incidence of Adverse Events as assessed by CTCAE v5.0Up to 15 years